Opinion
Video
BCG for treatment of NMIBC
Author(s):
Experts discuss the use of bacille Calmette-Guérin (BCG) as the standard treatment for high-risk non–muscle-invasive bladder cancer (NMIBC), when a patient is considered unresponsive to BCG, and how BCG shortages have impacted clinical practice and urologists in the community.
Video Player is loading.
This is a modal window.
The Video Cloud video was not found.
Error Code: VIDEO_CLOUD_ERR_VIDEO_NOT_FOUND
Session ID: 2025-05-16:5cffa0e9118593928fa63385 Player Element ID: vjs_video_911
Video content above is prompted by the following:
- BCG has long been the standard treatment for high-risk NMIBC.
- When do you consider a patient to be unresponsive to BCG?
- How have BCG shortages impacted your practice/urologists in the community
Related Videos
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
BRCA Mutations in mHSPC: Impact on Therapy Selection
Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
Defining and Managing BCG-Unresponsive NMIBC
Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
The Incidence of Prostate Cancer and Risk of Progression in Black Men
The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
The Evolvement of Imaging in ccRCC
Comparing Trials Studying Treatment Intensification In mHSPC
Impact of Robotic Procedures and Apps on Clinic Efficiency
Related Content
